Physician profile
Marsel Kogan
NPI 1487276853
$1,711.15
in general payments reported to CMS, 2019-2025
11 companies · $1,711 in 2025
The $1,711 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,711.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $371.87 | 2025 | Caplyta |
| Abbvie INC. | $339.45 | 2025 | |
| Alkermes, INC. | $252.81 | 2025 | Aristada, Lybalvi, Aristada Initio |
| Vanda Pharmaceuticals INC. | $237.25 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $127.93 | 2025 | Auvelity |
| Neurocrine Biosciences, INC. | $108.56 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $99.77 | 2025 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $60.23 | 2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $59.22 | 2025 | Rexulti |
| Livanova USA, INC. | $32.02 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Almatica Pharma LLC | $22.04 | 2025 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marsel Kogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.